NCT05756699
Evaluation of Proteome Multimarker Panel With Multiple Reaction Monitoring as a Surveillance for Hepatocellular Carcinoma
StatusActive, Not Recruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary completion moved 12 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Dec 31, 2025 to Dec 31, 2026
- Eligibility criteria expanded, about 7 words
- Secondary endpoints: details revised at 3 of 3 entries
- Notable Primary completion date: Dec 31, 2024 to Dec 31, 2025
- Study completion date: Dec 31, 2025 to Dec 31, 2026
- Minor Trial status: Not Yet Recruiting to Active, Not Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Mar 1, 2023 to Apr 10, 2023
- Collaborator revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
HCC detection rate
Timeframe: Up to 2 years
Secondary (3)
Early HCC detection rate
False referral rate
Positive predictive value
Arms and interventions
Diagnostic tests: multiple reaction monitoring (MRM)-based multimarker panel
Sites
1 site in 1 country
- Seoul National University HospitalSeoul, South Korea